Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "Formulations"

460 News Found

Glenmark's interim data from PMS Study on Favipiravir released
News | June 09, 2021

Glenmark's interim data from PMS Study on Favipiravir released

The study was conducted in patients with mild to moderate COVID-19


Lupin launches Digital Asthma Educator platform
News | June 08, 2021

Lupin launches Digital Asthma Educator platform

The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment


Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Shilpa Medicare Jadcherla facility gets GMP certification from Russia
Policy | May 29, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.


Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%
News | May 28, 2021

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%

The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year


Lupin receives US $50 mn on achieving cancer milestone
News | May 28, 2021

Lupin receives US $50 mn on achieving cancer milestone

MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination